These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17595327)

  • 1. The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor.
    To K; Zhao Y; Jiang H; Hu K; Wang M; Wu J; Lee C; Yokom DW; Stratford AL; Klinge U; Mertens PR; Chen CS; Bally M; Yapp D; Dunn SE
    Mol Pharmacol; 2007 Sep; 72(3):641-52. PubMed ID: 17595327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.
    Stratford AL; Habibi G; Astanehe A; Jiang H; Hu K; Park E; Shadeo A; Buys TP; Lam W; Pugh T; Marra M; Nielsen TO; Klinge U; Mertens PR; Aparicio S; Dunn SE
    Breast Cancer Res; 2007; 9(5):R61. PubMed ID: 17875215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.
    Yacoub A; Park MA; Hanna D; Hong Y; Mitchell C; Pandya AP; Harada H; Powis G; Chen CS; Koumenis C; Grant S; Dent P
    Mol Pharmacol; 2006 Aug; 70(2):589-603. PubMed ID: 16622074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.
    Wu J; Lee C; Yokom D; Jiang H; Cheang MC; Yorida E; Turbin D; Berquin IM; Mertens PR; Iftner T; Gilks CB; Dunn SE
    Cancer Res; 2006 May; 66(9):4872-9. PubMed ID: 16651443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
    Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
    Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
    Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
    Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.
    Lee TX; Packer MD; Huang J; Akhmametyeva EM; Kulp SK; Chen CS; Giovannini M; Jacob A; Welling DB; Chang LS
    Eur J Cancer; 2009 Jun; 45(9):1709-20. PubMed ID: 19359162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
    Weng SC; Kashida Y; Kulp SK; Wang D; Brueggemeier RW; Shapiro CL; Chen CS
    Mol Cancer Ther; 2008 Apr; 7(4):800-8. PubMed ID: 18413793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells.
    Park MA; Yacoub A; Rahmani M; Zhang G; Hart L; Hagan MP; Calderwood SK; Sherman MY; Koumenis C; Spiegel S; Chen CS; Graf M; Curiel DT; Fisher PB; Grant S; Dent P
    Mol Pharmacol; 2008 Apr; 73(4):1168-84. PubMed ID: 18182481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
    Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
    Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
    Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
    Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OSU-03012 in the treatment of glioblastoma.
    McCubrey JA; Lahair MM; Franklin RA
    Mol Pharmacol; 2006 Aug; 70(2):437-9. PubMed ID: 16675657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, Lee C, Yokom DW, Stratford AL, Klinge U, Mertens PR, Chen CS, Bally M, Yapp D, and Dunn SE (2007) The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) Prevents Y-Box Binding Protein-1 from Inducing Epidermal Growth Factor Receptor. Mol Pharmacol 72:641-652; doi:10.1124/mol.107.036111.
    Mol Pharmacol; 2016 Jul; 90(1):61. PubMed ID: 27284088
    [No Abstract]   [Full Text] [Related]  

  • 16. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors.
    Zhu J; Huang JW; Tseng PH; Yang YT; Fowble J; Shiau CW; Shaw YJ; Kulp SK; Chen CS
    Cancer Res; 2004 Jun; 64(12):4309-18. PubMed ID: 15205346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells.
    Finkbeiner MR; Astanehe A; To K; Fotovati A; Davies AH; Zhao Y; Jiang H; Stratford AL; Shadeo A; Boccaccio C; Comoglio P; Mertens PR; Eirew P; Raouf A; Eaves CJ; Dunn SE
    Oncogene; 2009 Mar; 28(11):1421-31. PubMed ID: 19151767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.
    Law JH; Li Y; To K; Wang M; Astanehe A; Lambie K; Dhillon J; Jones SJ; Gleave ME; Eaves CJ; Dunn SE
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoinositide-dependent kinase-1 and protein kinase Cδ contribute to endothelin-1 constriction and elevated blood pressure in intermittent hypoxia.
    Webster BR; Osmond JM; Paredes DA; DeLeon XA; Jackson-Weaver O; Walker BR; Kanagy NL
    J Pharmacol Exp Ther; 2013 Jan; 344(1):68-76. PubMed ID: 23093023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells.
    Berquin IM; Pang B; Dziubinski ML; Scott LM; Chen YQ; Nolan GP; Ethier SP
    Oncogene; 2005 Apr; 24(19):3177-86. PubMed ID: 15735691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.